Mr. Kranda led life sciences venture investments as managing director for Vulcan Capital through 2006 and continues to consult for Vulcan. He sits on the board of directors of several companies including BiPar Sciences and PTC Therapeutics.
George Schreiner, CEO of Raven, said: “We are delighted to have Michael’s continuing leadership as board chair, and I look forward to working with him to advance our goals.”